Aclaris Therapeutics Submits Investigational New Drug Application for ATI-50002 to Treat Alopecia Areata
August 02, 2017 08:00 ET
|
Aclaris Therapeutics, Inc.
MALVERN, Pa., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing...
UPDATE - Aclaris Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017
August 01, 2017 08:55 ET
|
Aclaris Therapeutics, Inc.
MALVERN, Pa., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biotechnology company, will release its second quarter financial results before the market...
Aclaris Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017
August 01, 2017 08:00 ET
|
Aclaris Therapeutics, Inc.
MALVERN, Pa., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biotechnology company, will release its first quarter financial results before the market...
Aclaris Therapeutics Initiates Phase 2b Clinical Trials of A-101 for Topical Treatment of Common Warts
June 29, 2017 08:00 ET
|
Aclaris Therapeutics, Inc.
MALVERN, Pa., June 29, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biotechnology company focused on identifying, developing and commercializing innovative...
Aclaris Therapeutics Announces Issuance of New U.S. Patent For A-101 Topical Solutions
June 13, 2017 08:00 ET
|
Aclaris Therapeutics, Inc.
MALVERN, Pa., June 13, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biotechnology company focused on developing innovative products in medical and...
Aclaris Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017
May 09, 2017 17:47 ET
|
Aclaris Therapeutics, Inc.
MALVERN, Pa., May 09, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Due to technical difficulties experienced by NASDAQ during today’s call, management has rescheduled its...
FDA Accepts Aclaris Therapeutics’ New Drug Application for Topical Treatment of Seborrheic Keratosis, a Common Skin Condition
May 09, 2017 16:05 ET
|
Aclaris Therapeutics, Inc.
MALVERN, Pa., May 09, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biotechnology company, today announced that the U.S. Food and Drug Administration has...
Aclaris Therapeutics Reports First Quarter 2017 Financial Results
May 09, 2017 16:01 ET
|
Aclaris Therapeutics, Inc.
MALVERN, Pa., May 09, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biotechnology company, today announced financial results for the first quarter of 2017...
Aclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Universalis and Alopecia Totalis
May 05, 2017 08:00 ET
|
Aclaris Therapeutics, Inc.
MALVERN, Pa., May 05, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative...
Aclaris Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017
May 01, 2017 16:08 ET
|
Aclaris Therapeutics, Inc.
MALVERN, Pa., May 01, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biotechnology company, will release its first quarter financial results before the...